Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1β production

Scandinavian Journal of Immunology

Volumn 66, Issue 5, 2007, Pages 555-562

  Li, J T ^a   Hou, F F ^a   Guo, Z J ^a   Shan, Y X ^a   Zhang, X ^a   Liu, Z Q ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; HUMAN SERUM ALBUMIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CULTURE MEDIUM; DOSE RESPONSE; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL; MEDIATOR RELEASE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; UPREGULATION;

C-REACTIVE PROTEIN; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETUS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPATOCYTES; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 35348932175     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02001.x     Document Type: Article

References (39)

1. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002 15 : 329 37.
2. Panichi V, Migliori M, De Pietro S et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001 23 : 551 62.
3. Schomig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia. Blood Purif 2000 18 : 327 32.
4. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000 35 : 469 76.
5. Noh H, Lee SW, Kang SW et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998 18 : 387 94.
6. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999 55 : 1899 911.
7. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001 59 : 407 14.
8. Lacson E Jr., Levin NW. C-reactive protein and end-stage renal disease. Semin Dial 2004 17 : 438 48.
9. Qureshi AR, Alvestrand A, Danielsson A et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998 53 : 773 82.
10. Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000 15 : 379 84.
11. Panichi V, Migliori M, De Pietro S et al. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif 2000 18 : 30 6.
12. Guarnieri G, Toigo G, Fiotti N et al. Mechanisms of malnutrition in uremia. Kidney Int 1997 Suppl. 62 : S41 4.
13. Goncalves S, Pecoits-Filho R, Perreto S et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006 21 : 2788 94.
14. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000 Suppl. 76 : S120 5.
15. Hou FF, Ren H, Guo ZJ, Chen PY, Liang M, Zhang X. Activation of receptor for advanced glycation end products: a mechanism for monocyte-mediated inflammation in chronic renal failure. Zhonghua Yi Xue Za Zhi 2004 84 : 1614 9 FF, Ren H, Owen WF Jr. et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004 15 : 1889 96.
16. Castell JV, Gomez-Lechon MJ, David M et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989 242 : 237 9.
17. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990 12 : 1179 86.
18. Miyata T, Iida Y, Ueda Y et al. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Kidney Int 1996 49 : 538 50.
19. Hou FF, Miyata T, Boyce J et al. beta(2)-microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001 59 : 990 1002.
20. Owen WF Jr., Hou FF, Stuart RO et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int 1998 53 : 1365 73.
21. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105 : 816 22.
22. Bauer J, Lengyel G, Thung SN, Jonas U, Gerok W, Acs G. Human fetal hepatocytes respond to inflammatory mediators and excrete bile. Hepatology 1991 13 : 1131 41.
23. Sells MA, Chernoff J, Cerda A et al. Long-term culture and passage of human fetal liver cells that synthesize albumin. In Vitro Cell Dev Biol 1985 21 : 216 20.
24. Gabay C, Genin B, Mentha G, Iynedjian PB, Roux-Lombard P, Guerne PA. IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin Exp Immunol 1995 100 : 306 13.
25. Yap SH, Moshage HJ, Hazenberg BP et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1991 1091 : 405 8.
26. Radford J, Bhathal PS. Purification of fetal rat hepatocytes. Cell Biol Int Rep 1985 9 : 677 88.
27. Hou FF, Chertow GM, Kay J et al. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 1997 51 : 1514 9.
28. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003 107 : 363 9.
29. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992 4 : 361 8.
30. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999 42 : 23 30.
31. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 : 2165 8.
32. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003 107 : 1783 90.
33. Higashi T, Sano H, Saishoji T et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997 46 : 463 72.
34. Festa A, Schmolzer B, Schernthaner G, Menzel EJ. Differential expression of receptors for advanced glycation end products on monocytes in patients with IDDM. Diabetologia 1998 41 : 674 80.
35. Goldman ND, Liu TY. Biosynthesis of human C-reactive protein in cultured hepatoma cells is induced by a monocyte factor(s) other than interleukin-1. J Biol Chem 1987 262 : 2363 8.
36. Zhang WR, Hou FF, Liu SX et al. Advanced glycation end products accelerate atherosclerosis via enhancement of oxidative stress. Zhonghua Yi Xue Za Zhi 2004 84 : 1066 72 BI, Schmidt AM. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004 21 : 1079 86.
37. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001 103 : 1194 7.
38. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997 52 : 1064 7.
39. Stam F, Schalkwijk CG, van Guldener C, ter Wee PM, Stehouwer CD. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals. Nephrol Dial Transplant 2006 21 : 677 82.